Investment Considerations Sigyn Therapeutics in May 2023 announced patent and trademark applications for its ImmunePrep commercialization platform. In October 2022, the company announced patent and trademark applications for ChemoPrep and ChemoPure to enhance chemotherapy and reduce toxicity. Sigyn Therapeutics in September 2022 announced plans to conduct first-in-human feasibility studies in end-stage renal disease patients. In … Continue reading “Sigyn Therapeutics Inc. (OTCQB: SIGY)”
Symbol | Release | Time |
---|---|---|
{{ release.qmtopics.qmsymbol[0].symbol }} | {{ release.headline }} | {{ release.datetime | amDateFormat:'hh:mm A'}} |